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After cardiovascular causes, infectious diseases are the next
most common cause of death for dialysis patients. The Japa-
nese Society for Dialysis Therapy reported an increased stan-
dardized mortality of 7.5-fold [95% conﬁdence limits (CI)
7.3–7.6] for infectious diseases between 2008 and 2009 com-
pared with the general Japanese population. The increased
mortality rates for dialysis patients were greatest for sepsis, fol-
lowed in descending order by peritonitis, inﬂuenza, tubercu-
losis and pneumonia [1]. Patients with chronic kidney disease
are more susceptible to some infections, as the azotaemic state
alters innate immunity, with reports of reduced monocyte
Toll-like receptor 4 expression [2], reduced B-lymphocyte cell
populations [3] and impaired polymorphonuclear chemotaxis
and phagocytosis [4]. It has also been proposed that changes
in the gastrointestinal microbiota, and increased intestinal per-
meability to endotoxin, lead to a persistent activation of the
innate immune system, resulting in the induction of immune-
regulatory mediators which then suppress both innate and
adaptive immunity [5]. Additionally, immune responses may
also be impaired by poor nutritional status, malnutrition and
vitamin D deﬁciency [6].
For many years, it has been recognized that haemodialysis
and peritoneal dialysis (PD) patients have a reduced response
to vaccination, in terms of developing seroprotective antibody
levels, to a number of the commonly available vaccines includ-
ing hepatitis B, pneumococcus, inﬂuenza A H1N1 and tetanus
toxoid [7]. The risk of mortality with chest infections in the
chronic dialysis patient has been reported to be 14- to 16-fold
higher than that for the general population, with >50% of
lower respiratory tract infections caused by Streptococcus
pneumoniae [8]. Lower respiratory tract infections have
additionally been reported to increase the relative risk for car-
diovascular events by 3.02 (95% CI: 2.87–3.02) in dialysis pa-
tients with pneumonia [9]. Most haemodialysis patients gain
ﬂuid between dialysis sessions [10], and this increase in
extracellular volume includes lung water. As such, lung water
content is increased even in healthy haemodialysis outpatients
without any respiratory symptoms prior to dialysis [11].
Whereas it was readily established that the mouth and upper
airway are extensively colonized by bacteria, it is only relatively
recently that it has been recognized that the lung is also nor-
mally colonized. The average person inhales 8000 L of air each
day, containing 104–106 bacterial cells per cubic metre. The in-
ternal surface area of the lung is some 30 times that of the skin
and the lung microbiome is determined by the balance
between microbial immigration, elimination and the relative
growth rates of different bacteria [12]. The proportion of resi-
dent to transient microbes remains to be determined in
healthy subjects, and it remains to be established how chronic
kidney disease and dialysis affect the lung microbiome. Surfac-
tant in the distal alveoli has bacteriostatic activity against some
bacterial species, and it is unknown whether this bacteriostatic
activity is impaired in dialysis patients. Similarly, other
changes in innate and adaptive immunity will affect the risk
for pulmonary infections. The lung microbiome is altered by
hypoxia [12], and increased water lung content in the dialysis
patient will increase hypoxia in dependent areas of the lung.
As such these changes may help explain the increased risk of
pulmonary infections in dialysis patients. This risk for pul-
monary infections appears to be much greater for haemodialy-
sis patients, and although this may be related to greater
changes in lung water content during the dialysis week com-
pared with PD patients, haemodialysis patients additionally
often travel together to and from dialysis centres and wait to-
gether at the start and end of dialysis sessions increasing the
risk of respiratory pathogen transmission, whereas PD is a
home-based therapy. Inﬂammatory changes in the lung have
been shown to lead to changes in other organs, the so-called
organ ‘cross talk’, and the combination of pulmonary inﬂam-
mation and increased lung water may account for the in-
creased cardiovascular events reported [9]. To reduce the risk
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of pulmonary infections, most economically developed coun-
tries recommend vaccination programmes for dialysis patients,
not only annual inﬂuenza vaccinations, but also pneumococcal
and haemophilus inﬂuenzae vaccines.
In addition to changes in the immune system, dialysis tech-
niques also potentially introduce additional risk factors for
infection. Haemodialysis patients who dialyze using central
venous access catheters are at the highest risk of access-related
infection, followed by arteriovenous grafts, then arteriovenous
ﬁstulae [13], and more recently it has been recognized that
needling practices may also affect the risk for infection, with
greater risk of ﬁstula-associated infection with buttonhole can-
nulation [14]. It is now acknowledged that the greatest risk for
mortality is when patients transition from non-dialysis chronic
kidney disease to dialysis, with mortality rates often greater than
those of patients opting for non-dialysis conservative care [15].
This excess mortality is linked to unplanned starts with central
venous catheter access [16]. As such many renal units have
introduced evidence-based clinical care bundles to reduce the
rates of haemodialysis access-related infections. Peritoneal
dialysis patients are also at increased risk of access-related exit-
site infections and peritonitis, and the International Society for
Peritoneal Dialysis similarly has recommended a series of inter-
ventions designed to reduce infection rates [17].
In this issue of the journal, Van Diepen et al. reviewed the
case notes of 452 incident dialysis patients starting dialysis
between 1997 and 2007 and followed while being treated by
their primary dialysis modality until 2009. Data on all infec-
tious complications were retrospectively collected and the
rates and types of infection were examined, according to dialy-
sis modality. Their study concluded that after taking into
account as many confounding factors as possible, infection
rates were higher for haemodialysis patients over the ﬁrst 6
months, but overall PD patients had a higher infection risk,
which was mainly attributable to dialysis-related technique in-
fections. Whether this increased risk for infections not requir-
ing hospitalization could simply be accounted for by PD
catheter exit infections is unclear. However, their results sug-
gested an increased risk for non-dialysis technique-related in-
fections in haemodialysis patients, such as sepsis and
pneumonia. Other studies have also tried to answer the ques-
tion as to whether the choice of dialysis modality confers a
higher risk for infection and results have been mixed, with
some reporting increased infection risk for haemodialysis and
others for PD. The major difference between Van Diepen
et al.’s study and earlier reports is their exhaustive effort to
adjust for possible confounding factors, using additional statis-
tical analysis, which adds extra validity to their conclusions.
The Khan comorbidity score, which has been previously vali-
dated in dialysis patients, was signiﬁcantly higher in those pa-
tients initiating haemodialysis compared with PD. During
their retrospective case note reviews, data on infections, which
occurred in both outpatient and hospital setting, were collated.
After adjustment for comorbidity [18], PD patients were
found to have had more infections. However, this group had a
greater number of less severe infections as the association
between infection risk and modality was weaker when only in-
fection-related hospitalizations were considered. The authors
detailed how they deﬁned infection during their case note
review, but the study would have been strengthened if they
had used a deﬁned standard set of agreed criteria, such as the
Centre for Disease Control/National Healthcare Safety
Network surveillance deﬁnitions [19]. Patients were followed
for an average of nearly 2 years on their ﬁrst dialysis modality,
and the risk for infection was higher in the haemodialysis
group for the ﬁrst 6 months, when patients were more likely to
be dialysing using central venous catheters. Data on vascular
access type was not available at the start of the study, with only
a snapshot of vascular access available at 3 months [16]. To
really help understand why infection risk fell during the ﬁrst 3
months in their haemodialysis cohort, changes in the propor-
tion of patients dialyzing using central venous catheters and
arteriovenous ﬁstulae are crucial.
To reduce infection in haemodialysis patients dialysing in
the Royal Free London network, we implemented a clinical
care bundle approach and introduced a number of evidence-
based interventions. From 2010 to 2012, arteriovenous ﬁstula
dialysis access rates increased from 64 to 78%. We introduced
a rolling 3 monthly Staphylococcus aureus nasal screening pro-
gramme, with all positive patients decolonized using a 5-day
course of nasal mupirocin and chlorhexidine body and hair
washing. Patients dialysing using a central venous catheter had
their exit-site examination recorded at each dialysis session
and antibiotics promptly started if there was evidence of local
infection. Chlorhexidine impregnated dressings were used at
the exit site for the ﬁrst 6 months and catheters locked with
46% citrate solution [20]. High-risk patients [i.e. those with a
previous S. aureus (SA) bacteraemia or those who are consist-
ently positive for SA on nasal carriage] had mupirocin addition-
ally applied at the exit site post-dialysis. An active surveillance
programme has been running since the start of 2010, with anti-
biotic start data, catheter infection rates and S. aureus bacter-
aemia (SAB) rates calculated and fedback to our individual
dialysis centres and at the dialysis group level every 6 months.
From 2010 to 2012, catheter access infection rates have fallen
from 0.99/1000 catheter days in the ﬁrst 6 months of 2010 to
0.42 in the latter 6 months of 2012 (R2 linear test of trend =
0.86). The reduction in both catheter-related SAB rates and
SAB rates overall were less marked over this time period
(Figure 1). This may well have been due to the rolling out of a
buttonhole ﬁstula needling policy as the ﬁrst-line approach for
needling arteriovenous ﬁstulae in 2010, following which we
then observed a rise in SAB in this set of patients [14]. Despite
the introduction of a strict ﬁstula disinfection and needle track-
ing policy, the infection rates did not fall and buttonhole need-
ling of ﬁstulae was subsequently withdrawn at the end of 2012.
In Van Diepen et al.’s study, PD patients predominantly suf-
fered from dialysis technique-related infections [21]. It has been
documented for some time that PD peritonitis remains the
commonest cause of patients transferring from PD to haemodi-
alysis [22]. Typically most cases are caused by Gram-positive or-
ganisms, which often migrate from the skin and colonize the
PD catheter [23]. Infection can also follow a failure to follow
sterile precautions when performing PD exchanges, external
contamination, gastrointestinal bacterial translocation, haema-
togenous spread and occasionally following gynaecological and
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rectal instrumentation. In addition, fungal infections may
occur, particularly after preceding broad-spectrum antibiotic
prescription [24]. At the time of their study, surveillance of
nasal S. aureus and eradication therapy was not part of their
routine clinical practice, and similarly neither were PD exit-site
antibiotics routinely prescribed [17], and as such the number of
exit site and tunnel infections reported may have been some-
what higher than would be expected today. Although the Inter-
national Society for Peritoneal Dialysis Clinical Guidelines
recommend the use of prophylactic exit site antibiotics, or nasal
antibiotics or both [17], and this may reduce the incidence of
exit-site infections, the effect on reducing peritonitis rates is
somewhat variable in clinical practice [25], with some centres
which have a low background rate of PD peritonitis reporting
minimal or no beneﬁcial effect, whereas centres with higher
background peritonitis rates reporting a reduction [26].
The dialysis infection literature would beneﬁt from an
equally thorough but more up-to-date review of the question
as to whether one dialysis modality confers a greater infection
risk. This information could then be used to counsel patients
when they have to choose a dialysis modality. As with other
surveillance data on infection, it could be used to target infec-
tion prevention interventions. Evidence-based guidelines for
the prevention of infection in dialysis patients are now readily
available [17, 27]. A review of infection rates is needed in from
those centres where these infection prevention bundles have
been introduced, as clinical practice varies widely. For
example, catheter insertion may be undertaken in surgical
theatres, radiological intervention suites or ward procedure
rooms with variation in skin cleaning preparations, use of
prophylactic antibiotics including antibiotic choice, dosage
and duration of prophylaxis, SA eradication therapy and pre-
insertion topical exit-site care. Central venous dialysis catheter
choice may also affect the risk for infection, not only in terms
of whether tunnelled and cuffed, but also the effect of differing
designs; dual lumen versus two single-lumen catheters,
biomaterials, catheter surface smoothness, size and compos-
ition of catheter cuffs and more recently coating with heparin,
antiseptics, antibiotics, silver and bismuth. Thereafter, catheter
care varies between centres in terms of whether aseptic precau-
tions are used for catheter connection and disconnection,
topical exit-site care and the use of catheter locks. As each of
these components of the clinical care bundle designed to
reduce infection risk has an economic cost, it is important for
both the patient and also for healthcare economics to ascertain
which components were most successful in reducing the risk
of infection, and equally which were least effective.
Although the introduction of clinical care infection preven-
tion bundles has reduced the incidence of catheter-associated
bacteraemias in haemodialysis patients, similar care pathways
have not substantially reduced the risk of peritonitis in Euro-
pean PD patients [26, 28]. Peritonitis rates have historically
been lower in Hong Kong and Japan compared with Northern
Europe, North America and Australia. Although there are dif-
ferences in climate, the bacterial causes of peritonitis are similar,
with Gram-positive skin commensals, followed by SA predom-
inating [17], suggesting that the skin microbiome is not sub-
stantially different. Dietary intake may differ, and changes in
the diet, for example, soy protein-rich diets and those rich in
plant-derived polysaccharides or resistant starches are known to
alter the gastrointestinal microbiota [5]. Increased gut perme-
ability and bacterial translocation are the most likely cause for
the majority of episodes of gut microbiome-derived Gram-nega-
tive and Gram-negative peritonitis. Both elderly haemodialysis
and PD patients are at increased risk of diverticular disease due
to the combination of ﬂuid restriction and dietary modiﬁcations
designed to reduce phosphate and potassium intake. Changes
in the gut microbiome alter innate and adaptive immunity,
leading to effects at distant sites. The combination of these
effects may account for the increased risk for developing peri-
tonitis with bacteria originating from the skin microbiome. On
the other hand, the introduction of neutral pH and low glucose
degradation product PD solutions has not made any signiﬁcant
impact on reducing peritonitis rates, suggesting that these
changes in peritoneal dialysate composition do not have any
major effect on the gut microbiome, and intestinal permeability.
Infection in dialysis patients remains an important health-
care problem. Studies have reported that although hospitaliza-
tions rates for dialysis patients have recently fallen overall,
those for infection-related admissions have not [29]. Preven-
tion should be the priority as infections are now harder to
treat with multi-drug resistant bacteria on the rise and few
newer antibiotics in the pipeline [30]. As such, centres should
ensure that patients are actively vaccinated against respiratory
pathogens to reduce the risk of pulmonary infections and also
aim to limit ﬂuid overload, in particular interdialytic ﬂuid
gains in haemodialysis patients. To reduce access-associated in-
fections, centres should aim to increase the number of patients
starting haemodialysis with arteriovenous ﬁstulae, so limiting
the use of central venous access catheters. Preventative infection
clinical care bundles have reduced catheter-associated bacterae-
mias, but have not been as successful in preventing peritonitis
in PD patients, and as such more research is required to reduce
the risk of peritonitis in this group of dialysis patients.
F IGURE 1 : The effect of changes in clinical practice with
introduction of active nasal and exit site screening and for haemodi-
alysis patients dialysing with central venous access catheters in
combination with a preventative combination bundle approach
on all and SA blood stream infections 2010–2012.
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